^
Association details:
| Biomarker: | DKK1 overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | sirexatamab (DKN-01) (DKK1 protein inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma
Published date:
03/29/2023
Excerpt:
We conducted an open-label, Phase 2 basket study with 2-stage design in patients with endometrial carcinoma (EC) and platinum-resistant/refractory epithelial ovarian cancer....DKN-01 monotherapy and in combination with paclitaxel was more effective in patients with high DKK1-expressing tumors compared to low-expressing tumors. DKN-01 monotherapy demonstrated an objective response rate [ORR] of 25.0% vs. 0%; disease control rate [DCR] of 62.5% vs. 6.7%; median progression-free survival [PFS] was 4.3 vs. 1.8 months, and overall survival [OS] was 11.0 vs. 8.2 months in DKK1-high vs DKK1-low patients. Similarly, DKN-01 in combination with paclitaxel demonstrated greater clinical activity in patients with DKK1-high tumors compared to DKK1-low tumors.
Secondary therapy:
paclitaxel
DOI:
10.1016/j.ygyno.2023.03.013
